Cogent’s bezuclastinib showed strong efficacy in a non-advanced SM trial, with a planned FDA submission expected by the end of 2025.
Latest Ratings for COGT
DateFirmActionFromTo Nov 2021HC Wainwright & Co.MaintainsBuy Oct 2021HC Wainwright & Co.Initiates Coverage OnBuy Dec 2020Piper SandlerInitiates Coverage OnOverweight